| __timestamp | MiMedx Group, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 381287000 |
| Thursday, January 1, 2015 | 133384000 | 452612000 |
| Friday, January 1, 2016 | 179997000 | 316800000 |
| Sunday, January 1, 2017 | 220119000 | 330100000 |
| Monday, January 1, 2018 | 258528000 | 265800000 |
| Tuesday, January 1, 2019 | 198205000 | 336200000 |
| Wednesday, January 1, 2020 | 181022000 | 423900000 |
| Friday, January 1, 2021 | 198359000 | 467000000 |
| Saturday, January 1, 2022 | 208789000 | 487000000 |
| Sunday, January 1, 2023 | 211124000 | 477100000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and MiMedx Group, Inc. over the past decade. From 2014 to 2023, United Therapeutics consistently outpaced MiMedx in SG&A spending, with an average annual expense of approximately $394 million, nearly double that of MiMedx's $188 million. Notably, United Therapeutics peaked in 2022 with expenses reaching $487 million, reflecting a strategic investment in growth and operations. Meanwhile, MiMedx showed a steady increase, culminating in a 2023 expense of $211 million, a 133% rise from 2014. This trend highlights the contrasting financial strategies of these companies, offering insights into their market positioning and operational priorities.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and United Therapeutics Corporation
Selling, General, and Administrative Costs: Johnson & Johnson vs MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of AbbVie Inc. and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or United Therapeutics Corporation
Cost Management Insights: SG&A Expenses for Biogen Inc. and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? United Therapeutics Corporation or ADMA Biologics, Inc.
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Wave Life Sciences Ltd.
United Therapeutics Corporation vs Travere Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.
CRISPR Therapeutics AG or MiMedx Group, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs MiMedx Group, Inc.